Cited by 136Macrophage Migration Inhibitory FactorChemokine receptors and signalingMechanisms of cancer metastasis

Macrophage Migration Inhibitory Factor Is Secreted by Rhabdomyosarcoma Cells, Modulates Tumor Metastasis by Binding to CXCR4 and CXCR7 Receptors and Inhibits Recruitment of Cancer-Associated Fibroblasts

Open access
Tarnowski, Maciej, Grymula, Katarzyna, Liu, Rui, Tarnowska, Joanna, Drukala, Justyna, Ratajczak, Janina, Mitchell, Robert A., Ratajczak, Mariusz Z. +1 more·2010·Molecular Cancer Research

Abstract

The overexpression of macrophage migration inhibitory factor (MIF) has been observed in many tumors and is implicated in oncogenic transformation and tumor progression. MIF activates CXCR2 and CD74 receptors and, as recently reported, may also bind to the stromal-derived factor-1 (SDF-1)–binding receptor CXCR4. Here, we report that human rhabdomyosarcoma (RMS) cell lines secrete MIF and that this chemokine (a) induces phosphorylation of mitogen-activated protein kinase (MAPK) p42/44 and AKT, (b) stimulates RMS cell adhesion, (c) enhances tumor vascularization, but surprisingly (d) decreases recruitment of cancer-associated fibroblasts (CAF). Because RMS cells used in our studies do not express CXCR2 and CD74 receptors, the biological effects of MIF on RMS cells depend on its interaction with CXCR4, and as we report here for the first time, MIF may also engage another SDF-1–binding receptor (CXCR7) as well. Interestingly, downregulation of MIF in RMS cells inoculated into immunodeficient mice led to formation of larger tumors that displayed higher stromal cell support. Based on these observations, we postulate that MIF is an important autocrine/paracrine factor that stimulates both CXCR4 and CXCR7 receptors to enhance the adhesiveness of RMS cells. We also envision that when locally secreted by a growing tumor, MIF prevents responsiveness of RMS to chemoattractants secreted outside the growing tumor (e.g., SDF-1) and thereby prevents release of cells into the circulation. On the other hand, despite its obvious proangiopoietic effects, MIF inhibits in CXCR2/CD74-dependent manner recruitment of CAFs to the growing tumor. Our data indicate that therapeutic inhibition of MIF in RMS may accelerate metastasis and tumor growth. Mol Cancer Res; 8(10); 1328–43. ©2010 AACR.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/1541-7786.mcr-10-0288

Cites

59 of 59 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Tarnowski, M., Grymula, K., Liu, R., Tarnowska, J., Drukala, J., Ratajczak, J., Mitchell, R. A., Ratajczak, M. Z., & Kucia, M.
Affiliations
  • Jagiellonian University (PL)
  • Authors' Affiliations: 1Stem Cell Institute at James Graham Brown Cancer Center, University of Louisville, Louisville, Kentucky; 2Department of Physiology, Pomeranian Medical University, Szczecin, Poland; and 3Department of Cell Biology, Faculty of Biochemistry, Biophysics and Biotechnology, Jagiellonian University, Cracow, Poland
Corresponding author
  • Ratajczak, Mariusz Z.
  • Kucia, Magda
Venue
Molecular Cancer Research
Published
2010-10-18
Volume
8
Issue
10
Pages
1328-1343
ISSN
  • 1541-7786 (ISSN-L)
  • 1557-3125
OpenAlex
W2128316913
Cited by
136
References
59
Citations by year
2026: 4 · 2025: 6 · 2024: 11 · 2023: 5 · 2022: 8 · 2021: 9 · 2020: 11 · 2019: 5 · 2018: 7 · 2017: 7 · 2016: 15 · 2015: 12 · 2014: 12 · 2013: 8 · 2012: 12
FWCI
3.29
Type
journal article
Language
en
Open access
Locations
  • Molecular Cancer Research (publishedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion)
Funders
  • National Institutes of Health (5r01ca106281-05)
  • National Cancer Institute (R01 CA106281-01, R01 CA106281)
  • National Institute of Diabetes and Digestive and Kidney Diseases (R01DK074720)
  • National Center for Research Resources (P20RR018733)
Topics
  • Life Sciences › Immunology and Microbiology › Immunology › Macrophage Migration Inhibitory Factor
  • Health Sciences › Medicine › Oncology › Chemokine receptors and signaling
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Mechanisms of cancer metastasis
Keywords
macrophage migration inhibitory factor, rhabdomyosarcoma, CXCR4, CXCR7, cancer-associated fibroblasts, metastasis, tumor angiogenesis, cell adhesion, MAPK phosphorylation, Akt signaling, chemokine receptors, tumor microenvironment, autocrine and paracrine signaling
MeSH terms
Animals, Cell Adhesion, Cell Line, Cell Migration Inhibition, Fibroblasts, Humans, Macrophage Migration-Inhibitory Factors, Neoplasm Invasiveness, Protein Binding, Rhabdomyosarcoma, Mice, SCID, Receptors, CXCR4, Cell Line, Tumor, Mice, Receptors, CXCR

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review